Adeno-associated Virus (AAV) Vector-based Gene Therapy Market

Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

220

Base Year:

2024

Nov - 2024

Format:

Report Code:

VMR-3397

Segments Covered

By Disease Type Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, Oncology
By Vector Serotype AAV1, AAV2, AAV5, AAV6, AAV8, AAV9
By Administration Route Intravenous, Intramuscular, Subcutaneous, Intraocular, Intracerebral
By End User Hospitals, Research Institutes, Biopharmaceutical Companies
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2024
Forecast Years:	2025 - 2034
Historical Years:	2019 - 2023
Revenue 2024:	USD 6.02 Billion
Revenue 2034:	USD 32.96 Billion
Revenue CAGR (2025 - 2034):	18.2%
Fastest Growing Region (2025 - 2034)	North America
Largest Region (2024):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2016 - 2028 (USD Million)
3. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Disease Type
  1. By Hematological Malignancies
  2. By Neurological Disorders
  3. By Cardiovascular Diseases
  4. By Ophthalmic Diseases
  5. By Oncology
4. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Vector Serotype
  1. By AAV1
  2. By AAV2
  3. By AAV5
  4. By AAV6
  5. By AAV8
  6. By AAV9
5. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Administration Route
  1. By Intravenous
  2. By Intramuscular
  3. By Subcutaneous
  4. By Intraocular
  5. By Intracerebral
6. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by End User
  1. By Hospitals
  2. By Research Institutes
  3. By Biopharmaceutical Companies
7. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
8. Market comparative analysis
North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2016 - 2028 (USD Million)
3. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
  1. By Hematological Malignancies
  2. By Neurological Disorders
  3. By Cardiovascular Diseases
  4. By Ophthalmic Diseases
  5. By Oncology
4. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
  1. By AAV1
  2. By AAV2
  3. By AAV5
  4. By AAV6
  5. By AAV8
  6. By AAV9
5. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
  1. By Intravenous
  2. By Intramuscular
  3. By Subcutaneous
  4. By Intraocular
  5. By Intracerebral
6. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
  1. By Hospitals
  2. By Research Institutes
  3. By Biopharmaceutical Companies
7. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Country
  1. U.S.
    1. U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. U.S. Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  2. Canada
    1. Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Canada Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  3. Mexico
    1. Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Mexico Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2016 - 2028 (USD Million)
3. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
  1. By Hematological Malignancies
  2. By Neurological Disorders
  3. By Cardiovascular Diseases
  4. By Ophthalmic Diseases
  5. By Oncology
4. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
  1. By AAV1
  2. By AAV2
  3. By AAV5
  4. By AAV6
  5. By AAV8
  6. By AAV9
5. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
  1. By Intravenous
  2. By Intramuscular
  3. By Subcutaneous
  4. By Intraocular
  5. By Intracerebral
6. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
  1. By Hospitals
  2. By Research Institutes
  3. By Biopharmaceutical Companies
7. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Country
  1. Germany
    1. Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Germany Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  2. UK
    1. UK Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. UK Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. UK Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. UK Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  3. France
    1. France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. France Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  4. Spain
    1. Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Spain Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  5. Italy
    1. Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Italy Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  6. BENELUX
    1. BENELUX Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. BENELUX Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. BENELUX Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. BENELUX Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  7. Rest of Europe
    1. Rest Of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Rest Of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Rest Of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Rest Of Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2016 - 2028 (USD Million)
3. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
  1. By Hematological Malignancies
  2. By Neurological Disorders
  3. By Cardiovascular Diseases
  4. By Ophthalmic Diseases
  5. By Oncology
4. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
  1. By AAV1
  2. By AAV2
  3. By AAV5
  4. By AAV6
  5. By AAV8
  6. By AAV9
5. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
  1. By Intravenous
  2. By Intramuscular
  3. By Subcutaneous
  4. By Intraocular
  5. By Intracerebral
6. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
  1. By Hospitals
  2. By Research Institutes
  3. By Biopharmaceutical Companies
7. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Country
  1. China
    1. China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. China Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  2. Japan
    1. Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Japan Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  3. India
    1. India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. India Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  4. South Korea
    1. South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. South Korea Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  5. South East Asia
    1. South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. South East Asia Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Rest of Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2016 - 2028 (USD Million)
3. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
  1. By Hematological Malignancies
  2. By Neurological Disorders
  3. By Cardiovascular Diseases
  4. By Ophthalmic Diseases
  5. By Oncology
4. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
  1. By AAV1
  2. By AAV2
  3. By AAV5
  4. By AAV6
  5. By AAV8
  6. By AAV9
5. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
  1. By Intravenous
  2. By Intramuscular
  3. By Subcutaneous
  4. By Intraocular
  5. By Intracerebral
6. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
  1. By Hospitals
  2. By Research Institutes
  3. By Biopharmaceutical Companies
7. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Country
  1. Brazil
    1. Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Brazil Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  2. Argentina
    1. Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Argentina Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  3. Rest of Latin America
    1. Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Rest of Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Disease Type
  1. By Hematological Malignancies
  2. By Neurological Disorders
  3. By Cardiovascular Diseases
  4. By Ophthalmic Diseases
  5. By Oncology
4. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Vector Serotype
  1. By AAV1
  2. By AAV2
  3. By AAV5
  4. By AAV6
  5. By AAV8
  6. By AAV9
5. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Administration Route
  1. By Intravenous
  2. By Intramuscular
  3. By Subcutaneous
  4. By Intraocular
  5. By Intracerebral
6. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by End User
  1. By Hospitals
  2. By Research Institutes
  3. By Biopharmaceutical Companies
7. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, by Country
  1. GCC Countries
    1. GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. GCC Countries Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  2. South Africa
    1. South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. South Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Disease Type
      1. By Hematological Malignancies
      2. By Neurological Disorders
      3. By Cardiovascular Diseases
      4. By Ophthalmic Diseases
      5. By Oncology
    2. Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Vector Serotype
      1. By AAV1
      2. By AAV2
      3. By AAV5
      4. By AAV6
      5. By AAV8
      6. By AAV9
    3. Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By Administration Route
      1. By Intravenous
      2. By Intramuscular
      3. By Subcutaneous
      4. By Intraocular
      5. By Intracerebral
    4. Rest of Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, By End User
      1. By Hospitals
      2. By Research Institutes
      3. By Biopharmaceutical Companies
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. Pfizer
2. BioMarin Pharmaceutical
3. Sarepta Therapeutics
4. Takeda
5. UniQure
6. Regenxbio
7. Adverum Biotechnologies
8. Spark Therapeutics (Roche)
9. Astellas Pharma
10. Bayer
11. Ultragenyx Pharmaceutical
12. Audentes Therapeutics (Astellas)
13. Homology Medicines
14. GenSight Biologics
15. Sangamo Therapeutics.
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 28-Nov-2024

Adeno-associated Virus (AAV) Vector-based Generket size to Reach USD 32.96 Bn by 2034 Therapy Ma

FAQ

Frequently Asked Question

What is the global demand for Adeno-associated Virus (AAV) Vector-based Gene Therapy in terms of revenue?

The global Adeno-associated Virus (AAV) Vector-based Gene Therapy valued at USD 6.02 Billion in 2024 and is expected to reach USD 32.96 Billion in 2034 growing at a CAGR of 18.2%.

Which are the prominent players in the market?

The prominent players in the market are Pfizer, BioMarin Pharmaceutical, Sarepta Therapeutics, Takeda, UniQure, Regenxbio, Adverum Biotechnologies, Spark Therapeutics (Roche), Astellas Pharma, Bayer, Ultragenyx Pharmaceutical, Audentes Therapeutics (Astellas), Homology Medicines, GenSight Biologics, Sangamo Therapeutics..

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 18.2% between 2025 and 2034.

What are the driving factors fueling the growth of the market.

The driving factors of the Adeno-associated Virus (AAV) Vector-based Gene Therapy include

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Adeno-associated Virus (AAV) Vector-based Gene Therapy in 2024.

Adeno-associated Virus (AAV) Vector-based Gene Therapy Market

Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Adeno-associated Virus (AAV) Vector-based Gene Therapy in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Quick Links

For Buying Inquiry

Adeno-associated Virus (AAV) Vector-based Gene Therapy Market

Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Adeno-associated Virus (AAV) Vector-based Gene Therapy in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Adeno-associated Virus (AAV) Vector-based Gene Therapy Market

Vantage Point Interactive Dashboard